摘要
目的探讨艾地苯醌联合依达拉奉对急性脑出血患者炎性因子和氧化应激水平的影响。方法选择2018年1月至2020年1月收治的急性脑出血患者98例,依据随机数字表法分为观察组与对照组,每组49例。对照组给予依达拉奉30 mg+生理盐水100 mL,iv gtt,bid;观察组在对照组治疗基础上予艾地苯醌片30 mg,po,tid。2组疗程均为2周。比较2组临床疗效,以及治疗前后日常生活活动能力(ADL)评分、神经功能缺损程度(NIHSS)评分、炎性因子和氧化应激水平。结果治疗后,观察组总有效率高于对照组(93.88%vs 75.60%,P<0.05);观察组ADL评分高于对照组[(67.17±4.67)vs(54.28±5.19),P<0.05], NIHSS评分低于对照组[(8.12±1.43)vs(13.59±2.08),P<0.05);观察组血清IL-6、IL-8和TNF-α浓度分别为(38.93±4.26)、(30.54±3.27)和(65.21±14.05)ng·L-1,分别低于对照组的(49.63±5.64)、(41.32±4.56)和(84.35±12.24)ng·L-1(P<0.05);观察组血清MDA浓度低于对照组[(7.84±1.68)μmol·L-1vs(12.13±2.31)μmol·L-1,P<0.05],而SOD浓度高于对照组[(148.39±15.26)U·mL-1vs(115.62±18.39)U·mL-1,P<0.05)。结论艾地苯醌联合依达拉奉对急性脑出血患者疗效显著,可减轻炎性反应,改善氧化应激。
AIM To investigate the effect of idebenone combined with edaravone on inflammatory factors and oxidative stress in patients with acute cerebral hemorrhage. METHODS A total of 98 patients with acute cerebral hemorrhage admitted to Ruian people’s Hospital from January 2018 to January 2020 were randomly divided into observation group(49 patients) and control group(49 patients) respectively. The control group was given edaravone 30 mg+100 mL normal saline, iv gtt, bid, and the observation group was combined with idebenone 30 mg, po, tid, on the basis of the control group. The course of treatment in both groups was 2 weeks. The ability of daily life(ADL), NIH Stroke Scale(NIHSS), inflammatory factors and oxidative stress were compared before and after treatment. RESULTS The total effective rate of the observation group was higher than that of the control group(93.88% vs 75.60%, P<0.05). After treatment, ADL score of the observation group was higher than that of the control group [(67.17±4.67) vs(54.28±5.19), P<0.05], while the NIHSS score was lower than that of the control group [(8.12±1.43) vs(13.59±2.08), P<0.05]. After treatment, in the observation group levels of IL-6, IL-8 and TNF-α were(38.93±4.26),(30.54±3.27),(65.21±14.05) ng·L-1, respectively, which were lower than those of the control group(49.63±5.64),(41.32±4.56) and(84.35±12.24)ng·L-1(P<0.05). After treatment, serum MDA level of the observation group was lower than that of the control group [(7.84±1.68) μmol·L-1 vs(12.13±2.31) μmol·L-1, P<0.05], while the SOD level of the observation group was higher than that of the control group [(148.39±15.26) U·mL-1 vs(115.62±18.39) U·mL-1, P<0.05]. CONCLUSION The combination of idebenone and edaravone is effective in the treatment of acute cerebral hemorrhage.
作者
郑海军
戴楠楠
戴凯茜
曾上飞
余一骏
郑侠
ZHENG Haijun;DAI Nannan;DAI Kaiqian;ZENG Shangfei;YU Yijun;ZHENG Xia(Department of Neurosurgery,Ruian People’s Hospital,Zhejiang Province,Ruian 325200,China)
出处
《中国临床药学杂志》
CAS
2020年第5期342-346,共5页
Chinese Journal of Clinical Pharmacy
关键词
艾地苯醌
依达拉奉
急性脑出血
疗效
神经功能缺损
炎性因子:氧化应激
idebenone
edaravone
acute cerebral hemorrhage
therapeutic effect
neurological deficit
inflammatory factor
oxidative stress
